Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Keros Therapeutics stock | $38.14

Learn how to easily invest in Keros Therapeutics stock.

Keros Therapeutics Inc is a biotechnology business based in the US. Keros Therapeutics shares (KROS) are listed on the NASDAQ and all prices are listed in US Dollars. Keros Therapeutics employs 44 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Keros Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KROS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Keros Therapeutics stock price (NASDAQ: KROS)

Use our graph to track the performance of KROS stocks over time.

Keros Therapeutics shares at a glance

Information last updated 2021-10-17.
Latest market close$38.14
52-week range$28.50 - $86.80
50-day moving average $35.19
200-day moving average $44.44
Wall St. target price$86.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.41

Buy Keros Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Keros Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Keros Therapeutics price performance over time

Historical closes compared with the close of $38.14 from 2021-10-20

1 week (2021-10-14) -4.22%
1 month (2021-09-22) 23.83%
3 months (2021-07-22) 0.63%
6 months (2021-04-22) -39.48%
1 year (2020-10-21) -26.85%
2 years (2019-10-18) N/A
3 years (2018-10-18) N/A
5 years (2016-10-18) N/A

Keros Therapeutics financials

Revenue TTM $100,000
Gross profit TTM $-32,538,000
Return on assets TTM -17.94%
Return on equity TTM -28.76%
Profit margin 0%
Book value $10.10
Market capitalisation $909.9 million

TTM: trailing 12 months

Shorting Keros Therapeutics shares

There are currently 1.0 million Keros Therapeutics shares held short by investors – that's known as Keros Therapeutics's "short interest". This figure is 20.8% up from 855,034 last month.

There are a few different ways that this level of interest in shorting Keros Therapeutics shares can be evaluated.

Keros Therapeutics's "short interest ratio" (SIR)

Keros Therapeutics's "short interest ratio" (SIR) is the quantity of Keros Therapeutics shares currently shorted divided by the average quantity of Keros Therapeutics shares traded daily (recently around 291021.12676056). Keros Therapeutics's SIR currently stands at 3.55. In other words for every 100,000 Keros Therapeutics shares traded daily on the market, roughly 3550 shares are currently held short.

However Keros Therapeutics's short interest can also be evaluated against the total number of Keros Therapeutics shares, or, against the total number of tradable Keros Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Keros Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Keros Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0715% of the tradable shares (for every 100,000 tradable Keros Therapeutics shares, roughly 72 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Keros Therapeutics.

Find out more about how you can short Keros Therapeutics stock.

Keros Therapeutics share dividends

We're not expecting Keros Therapeutics to pay a dividend over the next 12 months.

Keros Therapeutics overview

Keros Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts. .

Frequently asked questions

What percentage of Keros Therapeutics is owned by insiders or institutions?
Currently 14.639% of Keros Therapeutics shares are held by insiders and 81.473% by institutions.
How many people work for Keros Therapeutics?
Latest data suggests 44 work at Keros Therapeutics.
When does the fiscal year end for Keros Therapeutics?
Keros Therapeutics's fiscal year ends in December.
Where is Keros Therapeutics based?
Keros Therapeutics's address is: 99 Hayden Avenue, Lexington, MA, United States, 02421
What is Keros Therapeutics's ISIN number?
Keros Therapeutics's international securities identification number is: US4923271013
What is Keros Therapeutics's CUSIP number?
Keros Therapeutics's Committee on Uniform Securities Identification Procedures number is: 492327101

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site